

CERTIFICATION OF ENROLLMENT

SUBSTITUTE HOUSE BILL 1728

67th Legislature
2022 Regular Session

Passed by the House March 7, 2022
Yeas 97 Nays 1

**Speaker of the House of
Representatives**

Passed by the Senate March 3, 2022
Yeas 48 Nays 0

President of the Senate

Approved

Governor of the State of Washington

CERTIFICATE

I, Bernard Dean, Chief Clerk of the House of Representatives of the State of Washington, do hereby certify that the attached is **SUBSTITUTE HOUSE BILL 1728** as passed by the House of Representatives and the Senate on the dates hereon set forth.

Chief Clerk

FILED

**Secretary of State
State of Washington**

SUBSTITUTE HOUSE BILL 1728

AS AMENDED BY THE SENATE

Passed Legislature - 2022 Regular Session

State of Washington 67th Legislature 2022 Regular Session

By House Appropriations (originally sponsored by Representatives Maycumber, Cody, Callan, Eslick, Macri, Ramos, Griffey, Riccelli, and Leavitt; by request of Health Care Authority)

READ FIRST TIME 02/03/22.

1 AN ACT Relating to reauthorizing and amending dates for the total
2 cost of insulin work group; amending RCW 70.14.160; creating a new
3 section; and providing an expiration date.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 **Sec. 1.** RCW 70.14.160 and 2020 c 346 s 2 are each amended to
6 read as follows:

7 (1) The total cost of insulin work group is established. The work
8 group membership must consist of the insurance commissioner or
9 designee and the following members appointed by the governor:

10 (a) A representative from the prescription drug purchasing
11 consortium described in RCW 70.14.060;

12 (b) A representative from the pharmacy quality assurance
13 commission;

14 (c) A representative from an association representing independent
15 pharmacies;

16 (d) ~~((A representative from an association representing chain~~
17 ~~pharmacies;~~

18 ~~(e) A representative from each health carrier offering at least~~
19 ~~one health plan in a commercial market in the state;~~

20 ~~(f) A representative from each health carrier offering at least~~
21 ~~one health plan to state or public school employees in the state;~~

1 ~~(g)~~) A representative from an association representing health
2 carriers;

3 ~~((h))~~ (e) A representative from the public employees' benefits
4 board or the school employees' benefits board;

5 ~~((i))~~ (f) A representative from the health care authority;

6 ~~((j))~~ (g) A representative from ~~((a))~~ an association
7 representing pharmacy benefit ~~((manager that contracts with state~~
8 ~~purchasers))~~ managers;

9 ~~((k))~~ (h) A representative from a drug distributor or
10 wholesaler that distributes or sells insulin in the state;

11 ~~((l))~~ (i) A representative from a state agency that purchases
12 health care services and drugs for a selected population;

13 ~~((m))~~ (j) A representative from the attorney general's office
14 with expertise in prescription drug purchasing; ~~((and))~~

15 ~~((n))~~ (k) A representative from an organization representing
16 diabetes patients who is living with diabetes; and

17 (1) Four members of the public living with diabetes.

18 (2) The work group must review and design strategies to
19 ~~((reduce))~~;

20 (a) Reduce the cost of and total expenditures on insulin in this
21 state. Strategies the work group must consider include, but are not
22 limited to, a state agency becoming a licensed drug wholesaler, a
23 state agency becoming a registered pharmacy benefit manager, and a
24 state agency purchasing prescription drugs on behalf of the state
25 directly from other states or in coordination with other states; and

26 (b) Provide a once yearly 30-day supply of insulin to individuals
27 on an emergency basis. The strategies identified by the work group
28 shall include recommendations on eligibility criteria, patient
29 access, program monitoring, and pharmacy reimbursement, if
30 applicable.

31 (3) Staff support for the work group shall be provided by the
32 health care authority.

33 (4) By December 1, ~~((2020))~~ 2022, the work group must submit a
34 preliminary report detailing strategies to reduce the cost of and
35 total expenditures on insulin for patients, health carriers, payers,
36 and the state. The work group must submit a final report by July 1,
37 ~~((2021))~~ 2023, to the governor and the legislature. The final report
38 must include any statutory changes necessary to implement the
39 strategies.

40 (5) This section expires December 1, ~~((2022))~~ 2024.

1 NEW SECTION. **Sec. 2.** If specific funding for the purposes of
2 this act, referencing this act by bill or chapter number, is not
3 provided by June 30, 2022, in the omnibus appropriations act, this
4 act is null and void.

--- END ---